+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By Product, By Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders), By Regional Outlook and Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 235 Pages
  • August 2022
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5658981
The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.

Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others. These medications could greatly enhance human health. Protein distribution in appropriate amounts to the body to enable the precise functioning of various glands, as well as other organs in the body, is the basic concept behind protein therapy, which is conceptually related to gene therapy.



Genetically modified versions of naturally produced human proteins are called therapeutic proteins. They can be utilized to swap out proteins that are defective or lacking in a particular condition. They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness. The proteins produced by genetic engineering can be made to closely match the natural proteins they are meant to replace, or they can be improved by the addition of sugars and other compounds that prolong the protein's activity.

A protein that is defective or lacking in a certain condition can be replaced with therapeutic proteins. They can also increase the body's production of a helpful protein to lessen the effects of illness or chemotherapy. The proteins produced by genetic engineering may closely resemble the natural proteins they are intended to replace, or they may be improved.

COVID-19 Impact Analysis

The COVID-19 pandemic severely hampered the economy all over the world. A number of businesses were significantly demolished by the abrupt emergence of the pandemic. Moreover, several manufacturing and production facilities were closed owing to the outbreak due to the lockdown imposed by various governments within their countries. The protein therapeutics market was also disrupted in the initial period of the pandemic. Lockdown caused major delays within the development and delivery of crucial medical supplies. Attributed to this, the production of therapeutic protein was impeded.

Market Growth Factors

An increase in the cases of cancer across the world

One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world. Any disease that can affect any region of the body is referred to as cancer. Neoplasms and malignant tumors are other words that are used to denote this disease. One characteristic of cancer is the quick development of aberrant cells that expand outside of their normal borders, infiltrate other body components, and eventually move to other organs. This process is known as metastasis. The main reason why cancer patients die is because of widespread metastases within their bodies.

Rising focus of governments and regulatory bodies in accelerating the process of approval for this practice

A significant number of people in various developed, as well as developing nations who suffer from uncommon and complex diseases, depend on plasma-derived therapies every day as essential, life-saving medications. The need for these treatments, in particular immunoglobulins, has grown significantly and is still growing on a global scale. Plasma-derived therapies are treatments made from human plasma through a fractionation procedure in which the pertinent plasma proteins are isolated. The single largest component of human blood is called plasma, which is made up of proteins, salts, enzymes, and water. Primary and secondary immunodeficiencies, bleeding disorders, inhibitor deficiencies, and other rare diseases are all treated with plasma-derived medicines.

Market Restraining Factors

High manufacturing and administration cost

A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies. Because of high product prices, some therapies that patients need for a speedy and complete recovery are no longer available. In several nations, prices are additionally governed by law. Through their authority over national healthcare organizations, which can cover a significant portion of the cost of distributing drugs to consumers, government bodies restrict costs.

Product Outlook

On the basis of Product, the Protein Therapeutics Market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. In 2021, the Insulin segment garnered a significant revenue share of the protein therapeutics market. The rise in the growth of the segment is majorly attributed to the increasing cases of diabetes all over the world. Insulin is a natural hormone, which is produced by the pancreas. The lack of production of this hormone is the factor that stimulates the diabetes level of the human body.



Application Outlook

By application, the Protein Therapeutics Market is segregated into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others. In 2021, the metabolic disorders segment procured the biggest revenue share of the protein therapeutics market. The rise in the growth of the segment is due to the exponential demand for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segment's growth.

Regional Outlook

Region-wise, the Protein Therapeutics Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America held the largest revenue share of the protein therapeutics market. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. Moreover, North American countries are early adopters of several new technologies and approaches.

Cardinal Matrix - Protein Therapeutics Market Competition Analysis



The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Protein Therapeutics Market. Companies such as Merck & Co., Inc. Amgen, Inc., Eli Lilly and Company are some of the key innovators in Protein Therapeutics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.

Strategies deployed in Protein Therapeutics Market

; Partnerships, Collaborations and Agreements:

  • Aug-2022: Merck came into a collaboration with Orna Therapeutics, a biotechnology company. Following this collaboration, the companies is expected to work on the discovery, development, and commercialization of multiple programs, encompassing therapeutics and vaccines in the sector of infectious disease and oncology.
  • Mar-2022: Novo Nordisk joined hands with Massachusetts Institutes of Technology and Brigham and Women’s Hospital. Through this collaboration, the company aimed to leverage the distinct prospect to bring new transformational solutions to patients by utilizing its distinct capabilities.
  • Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.
  • Jan-2022: Merck teamed up with Absci, the drug, and target discovery company. Following this collaboration, Merck aimed to leverage Absci’s platform to utilize its compelling opportunity intending to develop new biologic candidates as well as explore complex protein expression.
  • Aug-2021: Eli Lilly and Company joined hands with Lycia Therapeutics, a biotechnology company. Following this collaboration, the companies aimed to focus on the development, manufacturing, and marketing of new targeted therapeutics leveraging the proprietary lysosomal targeting chimera protein degradation technology of Lycia.
  • Sep-2020: Merck collaborated with Seattle Genetics, an American biotechnology company. With this collaboration, the companies aimed to further expand the oncology portfolio of Merck in order to enhance the lives of cancer patients.

; Acquisitions and Mergers:

  • Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to integrate RSV investigational treatments of ReViral into its portfolio in order to acquire an offering of promising therapeutic candidates.
  • Nov-2021: Pfizer took over Trillium Therapeutics, a clinical-stage immuno-oncology company. This acquisition aimed to offer an impressive portfolio, including biologics, to Pfizer
  • Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobio's antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.
  • Jul-2021: Eli Lilly and Company completed its acquisition of Protomer, a pre-clinical stage biotechnology company. Under this acquisition, the company aimed to help Protomer in enhancing its diabetes range with its innovative technology.
  • Feb-2021: Merck took over VelosBio, a privately held clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to boost its expanding oncology portfolio while also strengthening its long-term growth potential.
  • Aug-2020: Johnson & Johnson completed its acquisition of Momenta Pharmaceuticals, a biotechnology company. This acquisition aimed to strengthen Janssen’s position in the autoimmune diseases sector and offer a major catalyst for sustained growth of the company.

; Approvals and Trials:

  • Sep-2020: Baxter International received the US FDA approval for its Clinimix and Clinimix E. The new formulations aimed to complement the offerings of medical formulations with their higher protein content.

Scope of the Study

Market Segments Covered in the Report:

By Product

  • Monoclonal Antibodies
  • Human Growth Hormone
  • Fusion Protein
  • Insulin
  • Erythropoietin
  • Interferon
  • Follicle Stimulating Hormone

By Application

  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Abbott Laboratories
  • Baxter International, Inc.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co., Inc.
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Pfizer, Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Protein Therapeutics Market, by Product
1.4.2 Global Protein Therapeutics Market, by Application
1.4.3 Global Protein Therapeutics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Product Launches and Product Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisition and Mergers: 2018, Mar - 2022, Jun) Leading Players
Chapter 4. Global Protein Therapeutics Market by Product
4.1 Global Monoclonal Antibodies Market by Region
4.2 Global Human Growth Hormone Market by Region
4.3 Global Fusion Protein Market by Region
4.4 Global Insulin Market by Region
4.5 Global Erythropoietin Market by Region
4.6 Global Interferon Market by Region
4.7 Global Follicle Stimulating Hormone Market by Region
Chapter 5. Global Protein Therapeutics Market by Application
5.1 Global Metabolic Disorders Market by Region
5.2 Global Immunologic Disorders Market by Region
5.3 Global Hematological Disorders Market by Region
5.4 Global Cancer Market by Region
5.5 Global Hormonal Disorders Market by Region
5.6 Global Genetic Disorders Market by Region
5.7 Global Others Market by Region
Chapter 6. Global Protein Therapeutics Market by Region
6.1 North America Protein Therapeutics Market
6.1.1 North America Protein Therapeutics Market by Product
6.1.1.1 North America Monoclonal Antibodies Market by Country
6.1.1.2 North America Human Growth Hormone Market by Country
6.1.1.3 North America Fusion Protein Market by Country
6.1.1.4 North America Insulin Market by Country
6.1.1.5 North America Erythropoietin Market by Country
6.1.1.6 North America Interferon Market by Country
6.1.1.7 North America Follicle Stimulating Hormone Market by Country
6.1.2 North America Protein Therapeutics Market by Application
6.1.2.1 North America Metabolic Disorders Market by Country
6.1.2.2 North America Immunologic Disorders Market by Country
6.1.2.3 North America Hematological Disorders Market by Country
6.1.2.4 North America Cancer Market by Country
6.1.2.5 North America Hormonal Disorders Market by Country
6.1.2.6 North America Genetic Disorders Market by Country
6.1.2.7 North America Others Market by Country
6.1.3 North America Protein Therapeutics Market by Country
6.1.3.1 US Protein Therapeutics Market
6.1.3.1.1 US Protein Therapeutics Market by Product
6.1.3.1.2 US Protein Therapeutics Market by Application
6.1.3.2 Canada Protein Therapeutics Market
6.1.3.2.1 Canada Protein Therapeutics Market by Product
6.1.3.2.2 Canada Protein Therapeutics Market by Application
6.1.3.3 Mexico Protein Therapeutics Market
6.1.3.3.1 Mexico Protein Therapeutics Market by Product
6.1.3.3.2 Mexico Protein Therapeutics Market by Application
6.1.3.4 Rest of North America Protein Therapeutics Market
6.1.3.4.1 Rest of North America Protein Therapeutics Market by Product
6.1.3.4.2 Rest of North America Protein Therapeutics Market by Application
6.2 Europe Protein Therapeutics Market
6.2.1 Europe Protein Therapeutics Market by Product
6.2.1.1 Europe Monoclonal Antibodies Market by Country
6.2.1.2 Europe Human Growth Hormone Market by Country
6.2.1.3 Europe Fusion Protein Market by Country
6.2.1.4 Europe Insulin Market by Country
6.2.1.5 Europe Erythropoietin Market by Country
6.2.1.6 Europe Interferon Market by Country
6.2.1.7 Europe Follicle Stimulating Hormone Market by Country
6.2.2 Europe Protein Therapeutics Market by Application
6.2.2.1 Europe Metabolic Disorders Market by Country
6.2.2.2 Europe Immunologic Disorders Market by Country
6.2.2.3 Europe Hematological Disorders Market by Country
6.2.2.4 Europe Cancer Market by Country
6.2.2.5 Europe Hormonal Disorders Market by Country
6.2.2.6 Europe Genetic Disorders Market by Country
6.2.2.7 Europe Others Market by Country
6.2.3 Europe Protein Therapeutics Market by Country
6.2.3.1 Germany Protein Therapeutics Market
6.2.3.1.1 Germany Protein Therapeutics Market by Product
6.2.3.1.2 Germany Protein Therapeutics Market by Application
6.2.3.2 UK Protein Therapeutics Market
6.2.3.2.1 UK Protein Therapeutics Market by Product
6.2.3.2.2 UK Protein Therapeutics Market by Application
6.2.3.3 France Protein Therapeutics Market
6.2.3.3.1 France Protein Therapeutics Market by Product
6.2.3.3.2 France Protein Therapeutics Market by Application
6.2.3.4 Russia Protein Therapeutics Market
6.2.3.4.1 Russia Protein Therapeutics Market by Product
6.2.3.4.2 Russia Protein Therapeutics Market by Application
6.2.3.5 Spain Protein Therapeutics Market
6.2.3.5.1 Spain Protein Therapeutics Market by Product
6.2.3.5.2 Spain Protein Therapeutics Market by Application
6.2.3.6 Italy Protein Therapeutics Market
6.2.3.6.1 Italy Protein Therapeutics Market by Product
6.2.3.6.2 Italy Protein Therapeutics Market by Application
6.2.3.7 Rest of Europe Protein Therapeutics Market
6.2.3.7.1 Rest of Europe Protein Therapeutics Market by Product
6.2.3.7.2 Rest of Europe Protein Therapeutics Market by Application
6.3 Asia Pacific Protein Therapeutics Market
6.3.1 Asia Pacific Protein Therapeutics Market by Product
6.3.1.1 Asia Pacific Monoclonal Antibodies Market by Country
6.3.1.2 Asia Pacific Human Growth Hormone Market by Country
6.3.1.3 Asia Pacific Fusion Protein Market by Country
6.3.1.4 Asia Pacific Insulin Market by Country
6.3.1.5 Asia Pacific Erythropoietin Market by Country
6.3.1.6 Asia Pacific Interferon Market by Country
6.3.1.7 Asia Pacific Follicle Stimulating Hormone Market by Country
6.3.2 Asia Pacific Protein Therapeutics Market by Application
6.3.2.1 Asia Pacific Metabolic Disorders Market by Country
6.3.2.2 Asia Pacific Immunologic Disorders Market by Country
6.3.2.3 Asia Pacific Hematological Disorders Market by Country
6.3.2.4 Asia Pacific Cancer Market by Country
6.3.2.5 Asia Pacific Hormonal Disorders Market by Country
6.3.2.6 Asia Pacific Genetic Disorders Market by Country
6.3.2.7 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Protein Therapeutics Market by Country
6.3.3.1 China Protein Therapeutics Market
6.3.3.1.1 China Protein Therapeutics Market by Product
6.3.3.1.2 China Protein Therapeutics Market by Application
6.3.3.2 Japan Protein Therapeutics Market
6.3.3.2.1 Japan Protein Therapeutics Market by Product
6.3.3.2.2 Japan Protein Therapeutics Market by Application
6.3.3.3 India Protein Therapeutics Market
6.3.3.3.1 India Protein Therapeutics Market by Product
6.3.3.3.2 India Protein Therapeutics Market by Application
6.3.3.4 South Korea Protein Therapeutics Market
6.3.3.4.1 South Korea Protein Therapeutics Market by Product
6.3.3.4.2 South Korea Protein Therapeutics Market by Application
6.3.3.5 Singapore Protein Therapeutics Market
6.3.3.5.1 Singapore Protein Therapeutics Market by Product
6.3.3.5.2 Singapore Protein Therapeutics Market by Application
6.3.3.6 Malaysia Protein Therapeutics Market
6.3.3.6.1 Malaysia Protein Therapeutics Market by Product
6.3.3.6.2 Malaysia Protein Therapeutics Market by Application
6.3.3.7 Rest of Asia Pacific Protein Therapeutics Market
6.3.3.7.1 Rest of Asia Pacific Protein Therapeutics Market by Product
6.3.3.7.2 Rest of Asia Pacific Protein Therapeutics Market by Application
6.4 LAMEA Protein Therapeutics Market
6.4.1 LAMEA Protein Therapeutics Market by Product
6.4.1.1 LAMEA Monoclonal Antibodies Market by Country
6.4.1.2 LAMEA Human Growth Hormone Market by Country
6.4.1.3 LAMEA Fusion Protein Market by Country
6.4.1.4 LAMEA Insulin Market by Country
6.4.1.5 LAMEA Erythropoietin Market by Country
6.4.1.6 LAMEA Interferon Market by Country
6.4.1.7 LAMEA Follicle Stimulating Hormone Market by Country
6.4.2 LAMEA Protein Therapeutics Market by Application
6.4.2.1 LAMEA Metabolic Disorders Market by Country
6.4.2.2 LAMEA Immunologic Disorders Market by Country
6.4.2.3 LAMEA Hematological Disorders Market by Country
6.4.2.4 LAMEA Cancer Market by Country
6.4.2.5 LAMEA Hormonal Disorders Market by Country
6.4.2.6 LAMEA Genetic Disorders Market by Country
6.4.2.7 LAMEA Others Market by Country
6.4.3 LAMEA Protein Therapeutics Market by Country
6.4.3.1 Brazil Protein Therapeutics Market
6.4.3.1.1 Brazil Protein Therapeutics Market by Product
6.4.3.1.2 Brazil Protein Therapeutics Market by Application
6.4.3.2 Argentina Protein Therapeutics Market
6.4.3.2.1 Argentina Protein Therapeutics Market by Product
6.4.3.2.2 Argentina Protein Therapeutics Market by Application
6.4.3.3 UAE Protein Therapeutics Market
6.4.3.3.1 UAE Protein Therapeutics Market by Product
6.4.3.3.2 UAE Protein Therapeutics Market by Application
6.4.3.4 Saudi Arabia Protein Therapeutics Market
6.4.3.4.1 Saudi Arabia Protein Therapeutics Market by Product
6.4.3.4.2 Saudi Arabia Protein Therapeutics Market by Application
6.4.3.5 South Africa Protein Therapeutics Market
6.4.3.5.1 South Africa Protein Therapeutics Market by Product
6.4.3.5.2 South Africa Protein Therapeutics Market by Application
6.4.3.6 Nigeria Protein Therapeutics Market
6.4.3.6.1 Nigeria Protein Therapeutics Market by Product
6.4.3.6.2 Nigeria Protein Therapeutics Market by Application
6.4.3.7 Rest of LAMEA Protein Therapeutics Market
6.4.3.7.1 Rest of LAMEA Protein Therapeutics Market by Product
6.4.3.7.2 Rest of LAMEA Protein Therapeutics Market by Application
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Baxter International, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trials:
7.2.5.2 Acquisition and Mergers:
7.3 Amgen, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.3.5.2 Acquisition and Mergers:
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 Eli Lilly And Company
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Acquisition and Mergers:
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Acquisition and Mergers:
7.7 Johnson & Johnson (Janssen Global Services, LLC)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental &Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.7.5.2 Acquisition and Mergers:
7.8 Pfizer, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional & Segmental Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Acquisition and Mergers:
7.9 Novo Nordisk A/S
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental & Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Sanofi S.A.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense

Companies Mentioned

  • Abbott Laboratories
  • Baxter International, Inc.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co., Inc.
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Pfizer, Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.

Methodology

Loading
LOADING...